Xencor, Inc. (XNCR) Dividend History

Xencor, Inc. (XNCR) is a biotechnology company focused on designing and developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Leveraging its proprietary XmAb technology platform, Xencor aims to create innovative therapies with improved efficacy and safety profiles. The company collaborates with various pharmaceutical partners and conducts research to advance its pipeline of targeted biologics.

465 N. Halstead St., Pasadena, CA, 91107
Phone: 626-305-5900
Website:

Dividend History

Xencor, Inc. currently does not pay dividends

Company News

  • Xencor shares surged 10.5% after the company announced a secondary stock offering to raise $175 million. The company plans to use the funds to support its pipeline development. However, earnings and revenue expectations for the upcoming quarter are negative, which may impact the stock's future performance.

    Benzinga
    Featured Companies: USNA
  • In the latest quarter, 5 analysts provided ratings for Xencor (NASDAQ:XNCR), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 1 2 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $35.4, a high estimate of $40.00, and a low estimate of $31.00. A decline of 17.29% from the prior average price target is evident in the current average. Investigating Analyst Ratings: An Elaborate Study A clear picture of Xencor's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Sean McCutcheon Raymond James Lowers Strong Buy $40.00 $58.00 Etzer Darout BMO Capital Lowers Outperform $32.00 $34.00 Gregory Renza RBC Capital Lowers Outperform $31.00 $32.00 David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xencor. This insight gives a snapshot of analysts' perspectives on the current state of the ...Full story available on Benzinga.com

    Benzinga
  • 6 analysts have shared their evaluations of Xencor (NASDAQ:XNCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0 0 Last 30D 0 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 3 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Xencor, presenting an average target of $33.0, a high estimate of $38.00, and a low estimate of $24.00. A decline of 17.91% from the prior average price target is evident in the current average. Deciphering Analyst Ratings: An In-Depth Analysis The analysis of recent analyst actions sheds light on the perception of Xencor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target David Nierengarten Wedbush Raises Outperform $36.00 $34.00 Kaveri Pohlman BTIG Lowers Buy $38.00 $56.00 Edward Tenthoff Piper Sandler Lowers Neutral $24.00 $37.00 Gregory Renza RBC Capital Maintains Outperform $32.00 - Etzer Darout BMO Capital Lowers Outperform $34.00 $38.00 David Nierengarten Wedbush Lowers Outperform $34.00 $36.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Xencor. This information provides a snapshot of ...Full story available on Benzinga.com

    Benzinga
  • Xencor (XNCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Zacks Investment Research
    Featured Companies: FENC
  • Ardelyx (ARDX) delivered earnings and revenue surprises of 15.38% and 25.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: ARDX
Dividend data last updated 06/07/2025 00:56:24 UTC